LeMaitre Vascular Stock Forecast, Price & News

LeMaitre Vascular (NASDAQ:LMAT) Frequently Asked Questions

Is LeMaitre Vascular a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for LeMaitre Vascular in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LeMaitre Vascular stock.
View analyst ratings for LeMaitre Vascular or view top-rated stocks.

How has LeMaitre Vascular's stock price been impacted by COVID-19?

LeMaitre Vascular's stock was trading at $26.10 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, LMAT shares have increased by 81.6% and is now trading at $47.40.
View which stocks have been most impacted by COVID-19.

Are investors shorting LeMaitre Vascular?

LeMaitre Vascular saw a decline in short interest during the month of October. As of October 15th, there was short interest totaling 1,000,000 shares, a decline of 23.1% from the September 30th total of 1,300,000 shares. Based on an average trading volume of 104,300 shares, the short-interest ratio is presently 9.6 days. Approximately 5.3% of the shares of the company are sold short.
View LeMaitre Vascular's Short Interest.

When is LeMaitre Vascular's next earnings date?

LeMaitre Vascular is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for LeMaitre Vascular.

How were LeMaitre Vascular's earnings last quarter?

LeMaitre Vascular, Inc. (NASDAQ:LMAT) posted its quarterly earnings results on Thursday, October, 28th. The medical instruments supplier reported $0.30 EPS for the quarter, missing the consensus estimate of $0.33 by $0.03. The medical instruments supplier earned $38.37 million during the quarter, compared to analysts' expectations of $39.05 million. LeMaitre Vascular had a trailing twelve-month return on equity of 14.15% and a net margin of 18.21%. The firm's quarterly revenue was up 5.4% compared to the same quarter last year. During the same period in the prior year, the business posted $0.37 earnings per share.
View LeMaitre Vascular's earnings history.

How often does LeMaitre Vascular pay dividends? What is the dividend yield for LeMaitre Vascular?

LeMaitre Vascular announced a quarterly dividend on Tuesday, October 26th. Shareholders of record on Friday, November 19th will be given a dividend of $0.11 per share on Thursday, December 2nd. This represents a $0.44 dividend on an annualized basis and a yield of 0.93%. The ex-dividend date of this dividend is Thursday, November 18th.
View LeMaitre Vascular's dividend history.

Is LeMaitre Vascular a good dividend stock?

LeMaitre Vascular pays an annual dividend of $0.44 per share and currently has a dividend yield of 0.94%. LeMaitre Vascular has been increasing its dividend for 10 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of LeMaitre Vascular is 33.33%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, LeMaitre Vascular will have a dividend payout ratio of 30.56% next year. This indicates that LeMaitre Vascular will be able to sustain or increase its dividend.
View LeMaitre Vascular's dividend history.

What guidance has LeMaitre Vascular issued on next quarter's earnings?

LeMaitre Vascular issued an update on its fourth quarter 2021 earnings guidance on Thursday, November, 4th. The company provided earnings per share guidance of $0.290-$0.340 for the period, compared to the Thomson Reuters consensus estimate of $0.340. The company issued revenue guidance of $39 million-$41 million, compared to the consensus revenue estimate of $40.18 million.

What price target have analysts set for LMAT?

5 brokerages have issued 1 year price objectives for LeMaitre Vascular's shares. Their forecasts range from $58.00 to $70.00. On average, they anticipate LeMaitre Vascular's share price to reach $64.25 in the next year. This suggests a possible upside of 35.5% from the stock's current price.
View analysts' price targets for LeMaitre Vascular or view top-rated stocks among Wall Street analysts.

Who are LeMaitre Vascular's key executives?

LeMaitre Vascular's management team includes the following people:

• George W. LeMaitre, Chairman & Chief Executive Officer
• David B. Roberts, President & Director (LinkedIn Profile)
• Trent G. Kamke, Senior Vice President-Operations (LinkedIn Profile)
• Joseph P. Pellegrino, CFO, Secretary, Treasurer & Director
• Jonathan W. Ngau, Vice President-Information Technology

What is George W. LeMaitre's approval rating as LeMaitre Vascular's CEO?

13 employees have rated LeMaitre Vascular CEO George W. LeMaitre on Glassdoor.com. George W. LeMaitre has an approval rating of 33% among LeMaitre Vascular's employees. This puts George W. LeMaitre in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of LeMaitre Vascular's key competitors?

Some companies that are related to LeMaitre Vascular include Beauty Health (SKIN), Merit Medical Systems (MMSI), iRhythm Technologies (IRTC), Nevro (NVRO), AtriCure (ATRC), Haemonetics (HAE), Axonics (AXNX), NuVasive (NUVA), Glaukos (GKOS), Procept BioRobotics (PRCT), Paragon 28 (FNA), Silk Road Medical (SILK), Inovio Pharmaceuticals (INO), Atrion (ATRI) and Cerus (CERS).
View all of LMAT's competitors.

What other stocks do shareholders of LeMaitre Vascular own?

Based on aggregate information from My MarketBeat watchlists, some companies that other LeMaitre Vascular investors own include (CGC), AbbVie (ABBV), Sociedad Química y Minera de Chile (SQM), Gilead Sciences (GILD), Aurora Cannabis (ACB), Aurora Cannabis (ACBFF), NVIDIA (NVDA), Adobe (ADBE), Boeing (BA) and salesforce.com (CRM).

What is LeMaitre Vascular's stock symbol?

LeMaitre Vascular trades on the NASDAQ under the ticker symbol "LMAT."

Who are LeMaitre Vascular's major shareholders?

LeMaitre Vascular's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (14.27%), Conestoga Capital Advisors LLC (8.52%), Copeland Capital Management LLC (4.45%), Geneva Capital Management LLC (4.14%), Dimensional Fund Advisors LP (3.12%) and Geode Capital Management LLC (1.54%). Company insiders that own LeMaitre Vascular stock include David B Roberts, George W Lemaitre, George W Lemaitre, John A Roush, Joseph P Pellegrino Jr, Lawrence J Jasinski and Trent G Kamke.
View institutional ownership trends for LeMaitre Vascular.

Which major investors are selling LeMaitre Vascular stock?

LMAT stock was sold by a variety of institutional investors in the last quarter, including Tygh Capital Management Inc., Two Sigma Investments LP, Bridge City Capital LLC, Dimensional Fund Advisors LP, Scout Investments Inc., Geneva Capital Management LLC, Janus Henderson Group PLC, and Krane Funds Advisors LLC. Company insiders that have sold LeMaitre Vascular company stock in the last year include David B Roberts, George W Lemaitre, John A Roush, Lawrence J Jasinski, and Trent G Kamke.
View insider buying and selling activity for LeMaitre Vascular or view top insider-selling stocks.

Which major investors are buying LeMaitre Vascular stock?

LMAT stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Pura Vida Investments LLC, Assenagon Asset Management S.A., Renaissance Technologies LLC, Copeland Capital Management LLC, Citadel Advisors LLC, Russell Investments Group Ltd., and Morgan Stanley.
View insider buying and selling activity for LeMaitre Vascular or or view top insider-buying stocks.

How do I buy shares of LeMaitre Vascular?

Shares of LMAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is LeMaitre Vascular's stock price today?

One share of LMAT stock can currently be purchased for approximately $47.40.

How much money does LeMaitre Vascular make?

LeMaitre Vascular has a market capitalization of $1.04 billion and generates $129.37 million in revenue each year. The medical instruments supplier earns $21.22 million in net income (profit) each year or $1.32 on an earnings per share basis.

How many employees does LeMaitre Vascular have?

LeMaitre Vascular employs 395 workers across the globe.

Does LeMaitre Vascular have any subsidiaries?

The following companies are subsidiares of LeMaitre Vascular: Artegraft, Bio Nova Holdings Pty Ltd, Bio Nova International Pty Ltd, Biomateriali, CardioCel, Clinical Instruments, Credent, Endomed, Ideas for Medicine, Inavein, LeMaitre Acquisition LLC, LeMaitre Cardial SAS, LeMaitre Medical Technology (Shanghai) Co., LeMaitre Vascular, LeMaitre Vascular AS, LeMaitre Vascular GK, LeMaitre Vascular GmbH, LeMaitre Vascular Pty Ltd, LeMaitre Vascular S.r.l., LeMaitre Vascular SAS, LeMaitre Vascular Singapore Pte Ltd, LeMaitre Vascular Spain, LeMaitre Vascular Switzerland GmbH, LeMaitre Vascular ULC, LifeSpan, PeriVu, ProCol, Restore Flow Allografts, RestoreFlow, Syntel and Python, TRIVEX, Tru-Incise (Eze-Sit) OUS, Tru-Incise (Eze-Sit) US, UnBalloon, VCS Clip, VascuCel, Vascular Architects, Vascular Innovations, Vascutech Acquisition LLC, Vermed, Whittaker Screen Printing, XenoSure, and Xenotis Pty Ltd.

When was LeMaitre Vascular founded?

LeMaitre Vascular was founded in 1983.

What is LeMaitre Vascular's official website?

The official website for LeMaitre Vascular is www.lemaitre.com.

Where are LeMaitre Vascular's headquarters?

LeMaitre Vascular is headquartered at 63 SECOND AVENUE, BURLINGTON MA, 01803.

How can I contact LeMaitre Vascular?

LeMaitre Vascular's mailing address is 63 SECOND AVENUE, BURLINGTON MA, 01803. The medical instruments supplier can be reached via phone at (781) 221-2266 or via fax at 781-425-5049.